Landscape analysis of m6A modification regulators related biological functions and immune characteristics in

Shuang Li1, Hui Liu1,2, Zhe Ruan1

  • 1Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.

Abstract

Insights

N6-methyladenosine (m6A) RNA modification plays a key role in myasthenia gravis (MG) pathogenesis. This study identified specific m6A regulators and their association with immune characteristics, offering new insights into MG

Area of Science:

  • Molecular Biology
  • Immunology
  • Genetics

Background:

  • N6-methyladenosine (m6A) modification is crucial in autoimmune disease development.
  • The role of m6A modification in myasthenia gravis (MG) is not well understood.
  • This study investigates m6A regulators' function and immune links in MG.

Purpose of the Study:

  • To explore the potential functions of m6A regulators in myasthenia gravis (MG).
  • To investigate the relationship between m6A regulators and immune characteristics in MG.
  • To identify distinct m6A modification patterns and their implications in MG.

Main Methods:

  • Analysis of Gene Expression Omnibus (GEO) dataset (GSE85452) for MG and healthy samples.
  • Identification and validation of differentially expressed m6A regulators using bioinformatics and RT-PCR.
  • Functional enrichment, correlation, unsupervised clustering, and WGCNA analyses to explore m6A regulator roles and immune associations.

Main Results:

  • CBLL1, RBM15, and YTHDF1 were upregulated in MG samples and validated by RT-PCR.
  • Target genes of these regulators are enriched in histone modification and Wnt signaling pathways.
  • RBM15 showed the strongest correlation with immune characteristics like natural killer cells and T follicular helper cells; two distinct m6A modification patterns were identified.

Conclusions:

  • m6A RNA modification significantly impacts the immune molecular mechanisms of MG.
  • The findings provide a novel perspective for understanding MG pathogenesis.
  • Dysregulated m6A regulators and their associated immune patterns are critical in MG.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.6K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K